我國新冠疫苗已接種6萬人
Trials of China's vaccines
我國新冠疫苗已接種6萬人
China currently has 13 vaccine candidates in clinical trials, of which three inactivated vaccines and one adenovirus vector vaccine are in phase three trials, said Tian Baoguo, deputy head of the Department of Science and Technology for Social Development of the Ministry of Science and Technology.
科技部社會發展科技司副司長田保國介紹，目前我國已有13個疫苗進入臨牀試驗階段。其中，三款滅活疫苗和一款腺病毒載體疫苗進入三期臨牀試驗。
And about 60,000 volunteers have been inoculated with the four vaccine candidates.
截至目前，共計約6萬名受試者接種，未收到嚴重不良反應的報告。
No severe adverse reaction has been reported among them, and preliminary results show that these vaccines are generally safe and only have minor side effects such as pain and bruising at the injection site, as well as temporary low-grade fever.
初步結果顯示，這些疫苗總體上是安全的，發生的不良反應基本爲輕度不良反應，比如接種部位局部疼痛、紅腫，以及一過性的低燒、發熱等。
Zheng Zhongwei, head of China's COVID-19 vaccine development task force, said the nation's annual COVID-19 vaccine production capacity could reach 610 million doses this year and will expand further next year.
科研攻關組疫苗研發專班工作組組長鄭忠偉介紹，預計今年年底我國新冠疫苗的年產能可達到6.1億劑，明年產能會在此基礎上有效擴大。
